PARTICULARS TO APPEAR ON THE OUTER PACKAGE

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Levafas Diamond Oral Suspension

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

3.0% w/v Levamisole Hydrochloride and
6.0% w/v Oxyclozanide

3. PHARMACEUTICAL FORM

Oral Suspension.
A bright yellow, viscous suspension.

4. PACKAGE SIZE

5. TARGET SPECIES

Cattle and sheep

6. INDICATION(S)

Levafas Diamond is a broad spectrum anthelmintic for use in the treatment and control of both gastro-intestinal and pulmonary nematode and adult liver fluke infections in cattle and sheep only.

Levafas Diamond should be used in cases of parasitic gastroenteritis and lungworm disease caused by mature and developing immature forms of those organisms sensitive to treatment with levamisole hydrochloride.

Lungworms:
Dictyocaulus spp

Gastrointestinal worms:
Haemonchus spp
Ostertagia spp (except inhibited Ostertagia larvae in cattle)
Nematodirus spp
Trichostrongylus spp
Cooperia spp
Oesophagostomum spp

Bunostomum spp

Levafas Diamond also removes most mature Fasciola spp (flukes) present in the bile duct of the liver.

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Levafas Diamond should be administered as an oral drench. Dosing must be carried out accurately using a suitable gun system, at a rate of 7.5 mg levamisole hydrochloride and 15 mg oxyclozanide per kg bodyweight.

To ensure administration of a correct dose, bodyweight should be determined as accurately as possible; accuracy of the dosing device should be checked. Animals should be dosed according to their individual weight, and not dosed as per the heaviest animal in the group, otherwise signs of overdose may occur (see overdose information).

Thoroughly shake the container well before use to ensure that the two active substances are homogeneously resuspended and therefore the animals receive the correct dose.

Do not mix with other products.

DOSAGE GUIDE

Double strength: Follow dosage instructions carefully

Cattle: 2.5 ml per 10 kg bodyweight

Bodyweight Dose

50 kg (approx. 1 cwt) 12.5 ml
100 kg (approx. 2 cwt) 25 ml
150 kg (approx. 3 cwt) 37.5 ml
200 kg (approx. 4 cwt) 50 ml
250 kg (approx. 5 cwt) 62.5 ml
300 kg (approx. 6 cwt) 75 ml

Cattle over 300 kg should be given a further 2.5 ml per additional 10 kg bodyweight.
**Sheep:** 0.5 ml per 2 kg bodyweight

**Bodyweight Dose**

- 10 kg (approx. 22 lb) 2.5 ml
- 20 kg (approx. 44 lb) 5 ml
- 30 kg (approx. 66 lb) 7.5 ml
- 40 kg (approx. 88 lb) 10 ml
- 50 kg (approx. 110 lb) 12.5 ml
- 60 kg (approx. 132 lb) 15 ml

Sheep over 60 kg should be given a further 1 ml per additional 4 kg bodyweight.

**8. WITHDRAWAL PERIOD**

Animals must not be slaughtered for human consumption during treatment.

Animals may be slaughtered for human consumption only after 5 days from the last treatment.

This product must not be used in cattle and sheep producing milk for human consumption.

**9. SPECIAL WARNING(S), IF NECESSARY**

Levafas Diamond may be administered to pregnant or lactating animals. However, care should be taken when treating heavily pregnant animals, and animals under stress from adverse weather conditions, poor nutrition, penning, handling etc.

Do not overdose. If recommended dosages are exceeded animals may exhibit signs of overdosage and toxicity. The effects of levamisole overdosage include impaired motor function i.e., muscle tremors, head shaking, increased salivation, facial swelling, oedema, scouring and in most severe cases, death.

At normal oxyclozanide dose levels, animals may show slight softening of the faeces with the occasional animal showing increased frequency of defecation and transient inappetence. Rarely, sheep may show an anaphylactic reaction with swelling of the head. Oxyclozanide overdosage may produce inappetence and loss of bodyweight, dullness and some loosening of faeces in sheep, and possibly diarrhoea. These effects are occasionally enhanced in animals with severe liver damage and/or dehydration at the time of dosing. Animals must not be treated within a period of 14 days before or after treatment with organophosphorus compounds.
Veterinary advice should be sought on appropriate dosing programmes and stock management to achieve adequate parasite control and to reduce the likelihood of anthelmintic resistance developing. Veterinary advice should be sought if the product does not achieve the desired clinical effect since other diseases, nutritional disturbances or anthelmintic resistance might be involved.

In cases of lungworm infections, coughing may persist for a considerable time following successful treatment with Downland Fluke and Worm Drench. This is due to tissue damage caused by the parasites.

After treatment animals should be moved to clean pasture in order to prevent re-infection. Levamisole activity is not affected by benzimidazole resistance.

Care should be taken to avoid the following practices because they increase the risk of development of resistance and could ultimately result in ineffective therapy:

- Too frequent and repeated use of anthelmintics from the same class, over an extended period of time.
- Underdosing, which may be due to underestimation of body weight, misadministration of the product, or lack of calibration of the dosing device (if any). Suspected clinical cases of resistance to anthelmintics should be further investigated using appropriate tests (e.g. Faecal Egg Count Reduction Test). Where the results of the test(s) strongly suggest resistance to a particular anthelmintic, an anthelmintic belonging to another pharmacological class and having a different mode of action should be used. Resistance to levamisole has been reported in *Teladorsagia*, *Cooperia* and *Trichostrongylus* species in sheep in a number of countries, including the EU. There are reports of resistance in *Haemonchus* in sheep outside the EU. Resistance to levamisole has been reported in *Teladorsagia* species in cattle in developed countries such as New Zealand. Therefore the use of this product should be based on local (regional, farm) epidemiological information about susceptibility of nematodes and recommendations on how to limit further selection for resistance to anthelmintics.

**User Warnings**

Do not eat, drink or smoke when using this product. Wash splashes from eyes and skin immediately. If irritation persists seek medical advice. Remove any contaminated clothing immediately. Wash hands and exposed skin after handling this product, and before meals. Levamisole can cause idiosyncratic reactions and serious blood disorders in a very small number of people. If symptoms such as dizziness, nausea, vomiting or abdominal discomfort are experienced when using this product, or sore mouth/throat or fever occur shortly afterwards, then medical advice should be sought immediately.

**10. EXPIRY DATE**
11. SPECIAL STORAGE CONDITIONS

Do not store above 25°C. Protect from light.

Keep the container in the outer carton.

12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE [Distribution category]

POM-VPS

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

KEEP OUT OF THE SIGHT AND REACH OF CHILDREN

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Norbrook Laboratories Limited, Newry, Co. Down, BT35 6JP, Northern Ireland.

16. MARKETING AUTHORISATION NUMBER(S)

Vm 02000/4080

17. MANUFACTURER’S BATCH NUMBER
MINIMUM PARTICULARS TO APPEAR ON IMMEDIATE PACKAGING UNITS
{Container Label}

1. NAME OF THE VETERINARY MEDICINAL PRODUCT
Levafas Diamond Oral Suspension

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES
3.0% w/v Levamisole Hydrochloride and
6.0% w/v Oxyclozanide

3. PHARMACEUTICAL FORM
Oral Suspension.
A bright yellow, viscous suspension.

4. PACKAGE SIZE
Multidose low-density polyethylene containers of 1 litre, 2.5 litres and 4 litres.

5. TARGET SPECIES
Cattle and sheep

6. INDICATION(S)
For the treatment and control of both gastrointestinal and pulmonary nematode infections, and adult liver fluke infections. Removes most mature Fasciola spp (flukes) present in the bile ducts of the liver.

7. METHOD AND ROUTE(S) OF ADMINISTRATION
For oral administration to cattle and sheep at a dose rate of 7.5mg levamisole hydrochloride and 15mg oxyclozanide per kg bodyweight. To ensure administration of a correct dose, bodyweight should be determined as accurately as possible; accuracy of the dosing device should be checked. Animals should be dosed according to their individual weight, and not dosed as per the heaviest animal in the group, otherwise signs of overdose may occur.

Thoroughly shake the container well before use to ensure that the two active substances are homogeneously resuspended and therefore the animals receive the correct dose.

Do not mix with other products.
DOSAGE GUIDE

Double strength: Follow dosage instructions carefully

Cattle: 2.5 ml per 10 kg bodyweight

Bodyweight Dose

50 kg (approx. 1 cwt) 12.5 ml
100 kg (approx. 2 cwt) 25 ml
150 kg (approx. 3 cwt) 37.5 ml
200 kg (approx. 4 cwt) 50 ml
250 kg (approx. 5 cwt) 62.5 ml
300 kg (approx. 6 cwt) 75 ml

Cattle over 300 kg should be given a further 2.5 ml per additional 10 kg bodyweight.

Sheep: 0.5 ml per 2 kg bodyweight

Bodyweight Dose

10 kg (approx. 22 lb) 2.5 ml
20 kg (approx. 44 lb) 5 ml
30 kg (approx. 66 lb) 7.5 ml
40 kg (approx. 88 lb) 10 ml
50 kg (approx. 110 lb) 12.5 ml
60 kg (approx. 132 lb) 15 ml

Sheep over 60 kg should be given a further 1 ml per additional 4 kg bodyweight.

8. WITHDRAWAL PERIOD

Animals must not be slaughtered for human consumption during treatment.

Animals may be slaughtered for human consumption only after 5 days from the last treatment.

This product must not be used in cattle and sheep producing milk for human consumption.
9. SPECIAL WARNING(S), IF NECESSARY

Animals must not be treated within a period of 14 days before or after treatment with organophosphorus compounds. Levamisole activity is not affected by benzimidazole resistance.

For the operator warnings and further information: See carton text.

10. EXPIRY DATE

11. SPECIAL STORAGE CONDITIONS

Do not store above 25°C. Protect from light.

Keep the container in the outer carton.

12. SPECIFIC PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Dispose of any unused product and empty containers in accordance with guidance from your local waste regulation authority.

13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE IF APPLICABLE [Distribution category]

POM-VPS

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

KEEP OUT OF THE SIGHT AND REACH OF CHILDREN

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Norbrook Laboratories Limited, Newry, Co. Down, BT35 6JP, Northern Ireland.

16. MARKETING AUTHORISATION NUMBER(S)

Vm 02000/4080

17. MANUFACTURER’S BATCH NUMBER

Approved: 23 June 2020